Wednesday, July 29, 2015

Analyst Tim Anderson on AstraZeneca: The long, slow crawl out

AstraZeneca, which had two announcements this week about staff cuts, also tried to spread a little pharmaceutical sunshine with an investor day in New York.

Analyst Tim Anderson on AstraZeneca: The long, slow crawl out

0 comments
AstraZeneca offices in England. The firm, which also has facilitiesin Delaware, announced more job cuts.
AstraZeneca offices in England. The firm, which also has facilitiesin Delaware, announced more job cuts.

AstraZeneca, which had two announcements this week about staff cuts, also tried to spread a little pharmaceutical sunshine with an investor day in New York.

"There were no major surprises or sudden solutions – which we weren't expecting anyway – suggesting a long, slow crawl out from beneath a host of past problems," Bernstein Research analyst Tim Anderson wrote in a note to clients. "Many of the proposed solutions appear reasonable (and in-line with expectations) yet some of them will probably be viewed by investors with a measure of caution and skepticism.

"On balance, we continue to think AZN is likely "at the bottom" and that the dividend is safe (current yield ~6%). This makes it tempting given low investor expectations and AZN's low relative valuation. The downside is that the stock stays at the bottom for a prolonged period because solutions like these generally play out only slowly, and that investors only earn their ~6% during this period of gradual rebuilding. Furthermore, earnings will very likely continue to go down for a number of years before they go up again."

Here is a link to the slides portion of the company's presentation.

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
letter icon Newsletter